A David Marais

List of Publications by Year
in descending order

59 papers	3,904 citations	236925 25 h-index	182427 51 g-index
60 all docs	60 docs citations	60 times ranked	3625 citing authors

#	Article	IF	Citations
1	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	13.7	813
2	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
3	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007, 193, 445-448.	0.8	323
4	Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. Circulation, 2011, 124, 2202-2207.	1.6	301
5	Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology, 2019, 51, 165-176.	0.6	215
6	Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2654-2660.	2.4	183
7	Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis, 2010, 208, 317-321.	0.8	115
8	Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. Journal of Lipid Research, 1997, 38, 2071-2078.	4.2	107
9	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) ExÂVivo. JACC Basic To Translational Science, 2016, 1, 419-427.	4.1	94
10	Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. Journal of Lipid Research, 1997, 38, 2071-8.	4.2	85
11	Familial hypercholesterolaemia. Clinical Biochemist Reviews, 2004, 25, 49-68.	3.3	83
12	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal, 2018, 39, 1162-1168.	2.2	81
13	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis, 2008, 197, 400-406.	0.8	80
14	Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 133-139.	2.3	61
15	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	2.8	57
16	Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 46-62.	6.1	52
17	Nutrition, modernity and the archaeological record: Coastal resources and nutrition among Middle Stone Age hunter-gatherers on the western Cape coast of South Africa. Journal of Human Evolution, 2014, 77, 64-73.	2.6	51
18	Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations. Clinical Chemistry, 2005, 51, 904-907.	3.2	45

#	Article	IF	Citations
19	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
20	Lomitapide and Mipomersenâ€"Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Current Atherosclerosis Reports, 2019, 21, 48.	4.8	36
21	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. Journal of Clinical Lipidology, 2017, 11, 12-23.e1.	1.5	33
22	The Apolipoprotein E2(Arg145Cys) Mutation Causes Autosomal Dominant Type III Hyperlipoproteinemia With Incomplete Penetrance. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 865-872.	2.4	33
23	Comparative aspects of the care of familial hypercholesterolemia in the â€œTen Countries Studyâ€: Journal of Clinical Lipidology, 2019, 13, 287-300.	1.5	32
24	Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. Journal of Lipid Research, 2003, 44, 212-217.	4.2	31
25	A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations. Diabetes, 2018, 67, 1086-1092.	0.6	30
26	Dysbetalipoproteinaemia--clinical and pathophysiological features. South African Medical Journal, 2002, 92, 892-7.	0.6	26
27	CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolemia among South African Indians. Clinical Genetics, 1997, 51, 394-398.	2.0	25
28	Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. Clinical Genetics, 1999, 55, 340-345.	2.0	24
29	Marine and terrestrial foods as a source of brain-selective nutrients for early modern humans in the southwestern Cape, South Africa. Journal of Human Evolution, 2016, 97, 86-96.	2.6	23
30	Apolipoprotein E and Atherosclerosis. Current Atherosclerosis Reports, 2021, 23, 34.	4.8	21
31	Recent advances in the treatment of homozygous familial hypercholesterolaemia. Current Opinion in Lipidology, 2013, 24, 288-294.	2.7	20
32	South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). South African Medical Journal, 2018, 108, 973-1000.	0.6	18
33	Dietary lipid modification for mild and severe dyslipidaemias. Proceedings of the Nutrition Society, 2013, 72, 337-341.	1.0	14
34	Tendon xanthomas: Not always familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1262-1265.	1.5	14
35	Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. Journal of Lipid Research, 2017, 58, 2180-2187.	4.2	14
36	Identification of a single MPV17 nonsenseâ€associated altered splice variant in 24 South African infants with mitochondrial neurohepatopathy. Clinical Genetics, 2018, 93, 1093-1096.	2.0	12

#	Article	IF	Citations
37	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis, 2018, 277, 327-333.	0.8	12
38	Cerebrotendinous xanthomatosis without neurological involvement. Journal of Internal Medicine, 2021, 290, 1039-1047.	6.0	12
39	Adiposity and the development of dyslipidemia in APOE Îµ2 homozygous subjects: A longitudinal analysis in two population-based cohorts. Atherosclerosis, 2021, 325, 57-62.	0.8	8
40	Rosuvastatin reduces nonâ€“high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Journal of Clinical Lipidology, 2008, 2, 418-425.	1.5	7
41	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. Atherosclerosis, 2018, 277, 470-476.	0.8	6
42	Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes. BMJ Case Reports, 2019, 12, e228199.	0.5	6
43	Familial hypercholesterolaemia: the Cape Town experience. South African Medical Journal, 2008, 98, 99-104.	0.6	6
44	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic To Translational Science, 2019, 4, 425-427.	4.1	5
45	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	2.4	5
46	Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. Clinica Chimica Acta, 2021, 520, 71-75.	1.1	4
47	Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report. South African Medical Journal, 1990, 77, 588-90.	0.6	4
48	Evolocumab for the treatment of homozygous familial hypercholesterolaemia. Expert Opinion on Orphan Drugs, 2016, 4, 789-798.	0.8	3
49	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. Current Atherosclerosis Reports, 2022, , 1.	4.8	2
50	Homozygous familial hypercholesterolemia and its treatment by inclisiran. Expert Opinion on Orphan Drugs, 2020, 8, 197-208.	0.8	1
51	The diagnosis and management of familial hypercholesterolaemia. European Review for Medical and Pharmacological Sciences, 2005, 9, 141-9.	0.7	1
52	Severe hypercholesterolaemia with a high risk of atherosclerosis may be precipitated by a high-sterol diet. South African Medical Journal, 2018, 108, 707.	0.6	0
53	Discovering hypertriglyceridaemia. South African Medical Journal, 2021, 111, 697.	0.6	0
54	Familial hypercholesterolaemia in South Africa: A reminder. South African Medical Journal, 2021, 111, 700.	0.6	0

#	Article	IF	Citations
55	Validation of PHASE for deriving N-acetyltransferase 2 haplotypes in the Western Cape mixed ancestry population. African Journal of Laboratory Medicine, 2020, 9, 988.	0.6	0
56	Familial hypercholesterolaemia and its management in South Africa. Cardiovascular Journal of Africa, 2019, 30, 247-247.	0.4	0
57	The mindâ€™s eye: A neuro-ophthalmological perspective on Niemann-Pick type C disease. African Vision and Eye Health, 2019, 78, .	0.2	0
58	Hypertriglyceridaemia in adolescents may have serious complications. South African Medical Journal, 2022, 112, 307-312.	0.6	0
59	Hypertriglyceridaemia in adolescents may have serious complications.. South African Medical Journal, 2022, 112, 307-312.	0.6	0